Case Reports
[Histamine H-2 receptor antagonists and medical treatment of Zollinger-Ellison syndrome]
[Article in
French]
- PMID: 29338
Item in Clipboard
Case Reports
[Histamine H-2 receptor antagonists and medical treatment of Zollinger-Ellison syndrome]
[Article in
French]
Sem Hop.
1978 Mar.
Abstract
Cimetidine was studied in 8 cases of Zollinger-Ellison syndrome. The average dose was 1,2 g a day for 14 to 195 days. The treatment was remarkably effective in 2 cases, but only partial or temporary improvement was noted in 3 other cases. The last 3 patients failed to respond to treatment. The possibility of a rebound phenomenon requires strict clinical and biological supervision.
Similar articles
-
[Efficacy of combined anti-secretory treatment (cimétidine and pirenzepin) in Zollinger-Ellison syndrome].Nouv Presse Med. 1977 Nov 12;6(38):3544-5. Nouv Presse Med. 1977. PMID: 23518 French. No abstract available.
-
Zollinger-Ellison syndrome unresponsive to cimetidine.Am J Gastroenterol. 1979 Aug;72(2):168-70. Am J Gastroenterol. 1979. PMID: 474557
-
Long-term treatment with histamine H2-receptor antagonists in Zollinger-Ellison syndrome.Am J Gastroenterol. 1978 Sep;70(3):286-91. Am J Gastroenterol. 1978. PMID: 717379
-
H2-receptor antagonists in perspective.Mayo Clin Proc. 1978 Mar;53(3):184-90. Mayo Clin Proc. 1978. PMID: 24155 Review.
-
H2 receptor antagonists.Am J Hosp Pharm. 1978 Feb;35(2):141-5. Am J Hosp Pharm. 1978. PMID: 24338 Review.
Cited by
-
Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature.Medicine (Baltimore). 2006 Nov;85(6):295-330. doi: 10.1097/01.md.0000236956.74128.76. Medicine (Baltimore). 2006. PMID: 17108778 Free PMC article.
-
Successful Lifetime/Long-Term Medical Treatment of Acid Hypersecretion in Zollinger-Ellison Syndrome (ZES): Myth or Fact? Insights from an Analysis of Results of NIH Long-Term Prospective Studies of ZES.Cancers (Basel). 2023 Feb 21;15(5):1377. doi: 10.3390/cancers15051377. Cancers (Basel). 2023. PMID: 36900170 Free PMC article.